Trial Profile
A phase III randomized, double-blind, double-dummy, multi-center study to compare the efficacy, safety, and tolerability of tolterodine extended release capsule with tolterodine immediate release tablet in subjects with symptoms of overactive bladder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Tolterodine (Primary)
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 29 Dec 2009 Actual end date (October 2006) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Actual patient number (260) added as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.